Clicca qui per scaricare

Autismo ed infi ammazione
Titolo Rivista: PNEI REVIEW 
Autori/Curatori: Dario Siniscalco 
Anno di pubblicazione:  2017 Fascicolo: Lingua: Italiano 
Numero pagine:  8 P. 33-40 Dimensione file:  1093 KB
DOI:  10.3280/PNEI2017-001004
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più:  clicca qui   qui 


L’autismo ed i disturbi dello spettro autistico (DSA) comprendono patologie complesse dello sviluppo neurologico caratterizzati da difetti cognitivi, dell’interazione sociale e della comunicazione, del linguaggio e problemi comportamentali. L’interazione tra fattori genetici ed ambientali è alla base di tale patologia, anche se la patogenesi non è ancora del tutto chiara. Una serie di eventi biochimici sono associati con l’autismo, così come disfunzioni immunitarie e problemi gastrointestinali. La componente infiammatoria ed immuno-mediata riveste particolare importanza nello sviluppo di questi disordini. Recenti evidenze sottolineano come il sistema molecolare degli endocannabinoidi sia alla base della disfunzione immunitaria ed infiammatoria.


Keywords: Autismo, endocannabinoidi, neuro-immunomodulazione

  1. Al-Ayadhi LY e Mostafa GA (2013) Elevated serum levels of macrophage-derived chemokine and thymus and activation-regulated chemokine in autistic children, J Neuroinflammation 10:72. doi.org/10.1186/1742-2094-10-72
  2. Agudelo M, Newton C, Widen R, et al. (2008) Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murinepurified B lymphocytes, J Neuroimm Pharmacol 3(1):35-42. doi.org/10.1007/s11481-007-9088-9
  3. Ashwood P, Wills S e Van de Water J (2006) The immune response in autism: A new frontier for autism research, J Leukocyte Biol 80(1):1-15. doi.org/10.1189/jlb.1205707
  4. Basu S e Dittel BN (2011) Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease, Immun Res 51(1):26-38. doi.org/10.1007/s12026-011-8210-5
  5. Buescher AV, Cidav Z, Knapp M, et al. (2014) Costs of autism spectrum disorders in the United Kingdom and the United States, JAMA Pediatr 168(8):72172-72178. doi.org/10.1001/jamapediatrics.2014.210
  6. Cencioni MT, Chiurchiù V, Catanzaro G, et al. (2010) Anandamide suppressesproliferation and cytokine release from primary human T-lymphocytesmainly via CB2 receptors, PLoS One 5(1):e8688. doi.org/10.1371/journal.pone.0008688
  7. Christensen DL, Baio J, Van Naarden Braun K, et al. (2016) Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012, MMWR Surveill Summ 65(3):1-23. doi.org/10.15585/mmwr.ss6503a1
  8. De Theije CG, Wopereis H, Ramadan M, et al. (2014) Altered gut microbiota and activity in a murine model of autism spectrum disorders, Brain Behav Immun 37:197-206. doi.org/10.1016/j.bbi.2013.12.005
  9. Enstrom AM, Onore CE, Van de Water JA, et al. (2010) Differential monocyte responses to TLR ligands in children with autism spectrum disorders, Brain Behav Immun 24(1):64-71. doi.org/10.1016/j.bbi.2009.08.001
  10. Földy C, Malenka RC e Südhof TC (2013) Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling, Neuron 78(3):498-509. doi.org/10.1016/j.neuron.2013.02.036
  11. Garbett K, Ebert PJ, Mitchell A et al. (2008) Immune transcriptome alterations in the temporal cortex of subjects with autism, Neurobiol Dis 30(3):303-311. doi.org/10.1016/j.nbd.2008.01.012
  12. Gottfried C, Bambini-Junior V, Francis F, et al. (2015) The Impact of Neuroimmune Alterations in Autism Spectrum Disorder, Front Psychiatry 6:121. doi.org/10.3389/fpsyt.2015.00121
  13. Gupta S, Samra D e Agrawal S (2010) Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin, J Clin Immunol 30:S90-S96. doi.org/10.1007/s10875-010-9402-9
  14. Hume DA (2008) Macrophages as APC and the dendritic cell myth, J Immunol 181:5829-5835. doi.org/10.4049/jimmunol.181.9.5829
  15. Ishiguro H, Horiuchi Y, Ishikawa M, et al. (2010) Brain cannabinoid CB2 receptor in schizophrenia, Biol Psych 67(10):974-982. doi.org/10.1016/j.biopsych.2009.09.024
  16. Jean-Gilles L, Gran B e Constantinescu CS (2010) Interaction between cytokines, cannabinoids and the nervous system, Immunobiology 215(8):606-610. doi.org/10.1016/j.imbio.2009.12.006
  17. Li X, Chauhan A, Sheikh AM, et al. (2009) Elevated immune response in the brain of autistic patients, J Neuroimmunol 207(1–2):111-116. doi.org/10.1016/j.jneuroim.2008
  18. Meltzer A e Van de Water J (2017) The Role of the Immune System in Autism Spectrum Disorder, Neuropsychopharmacology 42(1):284-298. doi.org/10.1038/npp.2016.158
  19. Molloy CA, Morrow AL, Meinzen-Derr J, et al. (2006) Elevated cytokine levels in children with autism spectrum disorder, J Neuroimmunol 172(1-2):198-205. doi.org/10.1016/j.jneuroim.2005.11.007
  20. Robinson SA, Loiacono RE, Christopoulos A, et al. (2010) The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling, Brain Res 1343:153-167. doi.org/10.1016/j.brainres.2010.04.031
  21. Schneider M e Koch M (2005) Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: Effects of chronic pubertal cannabinoid treatment, Neuropsychopharmacology 30(5):944-957. doi.org/10.1038/sj.npp.1300634
  22. Schultz ST (2010) Can autism be triggered by acetaminophen activation of the endocannabinoid system?, Acta Neurobiol Exp (Wars) 70(2):227-231.
  23. Schultz ST e Gould GG (2016) Acetaminophen Use for Fever in Children Associated with Autism Spectrum Disorder, Autism Open Access 6(2):170. doi.org/10.4172/2165-7890.1000170
  24. Servadio M, Melancia F, Manduca A, et al. (2016) Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid, Transl Psychiatry 6(9):e902. doi.org/10.1038/tp.2016.182
  25. Siniscalco D, Sapone A, Cirillo A, et al. (2012a) Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?, J Biomed Biotechnol 2012:480289. doi.org/10.1155/2012/480289
  26. Siniscalco D, Sapone A, Giordano C, et al. (2012b) The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients, J Autism Dev Disord 42(7):1403-1410. doi.org/10.1007/s10803-011-1373-z
  27. Siniscalco D, Di Marsilio A e Antonucci N (2013a) Ethics in Autism Care, Autism 3:e119. doi.org/10.4172/2165-7890.1000e119
  28. Siniscalco D, Cirillo A, Bradstreet JJ, et al. (2013b) Epigenetic findings in autism: new perspectives for therapy, Int J Environ Res Public Health 10(9):4261-4273. doi.org/10.3390/ijerph10094261
  29. Siniscalco D, Sapone A, Giordano C, et al. (2013c) Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders, J Autism Dev Disord 43(11):2686-2695. doi.org/10.1007/s10803-013-1824-9
  30. Siniscalco D e Antonucci N (2014) Role of proteases in autism spectrum disorders, in: Chakraborti S e Dhalla NS (eds) 2014, Proteases in Health and Disease, Springer Science, New York, pp.327-333.
  31. Siniscalco D, Antonucci N, Maione S, et al. (2014a) Receptor/regulatory molecules pattern changes: caspases in autism spectrum disorders, in: Patel VB, Preedy VR e Martin CR (eds) 2014, A comprehensive guide to autism. Biochemical aspects in autism spectrum disorders, Springer-Verlag, New York, pp. 1245-1257.
  32. Siniscalco D (2014b) Endocannabinoid System as Novel Therapeutic Target for Autism Treatment, Autism Open Access 4:e122. doi.org/10.4172/2165-7890.1000e122
  33. Siniscalco D (2014c) Adhesion G-protein Coupled Receptors in Autism, Autism-Open Access 4:e126. doi.org/10.4172/2165-7890.1000e126
  34. Siniscalco D, Bradstreet JJ, Cirillo A, et al. (2014d) The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages, J Neuroinflammation 11:78. doi.org/10.1186/1742-2094-11-78

Dario Siniscalco, in "PNEI REVIEW" 1/2017, pp. 33-40, DOI:10.3280/PNEI2017-001004

   

FrancoAngeli è membro della Publishers International Linking Association associazione indipendente e no profit per facilitare l'accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche